Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGI-110 in Advanced HCC Post-Sorafenib
NCT01752933Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- Sep 2015
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in hepatocellular carcinoma (HCC), sponsored by Astex Pharmaceuticals. Primary endpoint: Disease Control Rate at 16 weeks. Started Dec 2012; status: completed.
02
Drugs
guadecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01752933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01752933.